Glenmark Life Sciences Ltd
NSE:GLS
Glenmark Life Sciences Ltd
Cost of Revenue
Glenmark Life Sciences Ltd
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
G
|
Glenmark Life Sciences Ltd
NSE:GLS
|
Cost of Revenue
-₹10B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Cost of Revenue
-₹82.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
Cipla Ltd
NSE:CIPLA
|
Cost of Revenue
-₹88.2B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-9%
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Cost of Revenue
-₹105.3B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-15%
|
|
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
|
Cost of Revenue
-₹63.1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-9%
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Cost of Revenue
-₹27.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-9%
|
See Also
What is Glenmark Life Sciences Ltd's Cost of Revenue?
Cost of Revenue
-10B
INR
Based on the financial report for Mar 31, 2024, Glenmark Life Sciences Ltd's Cost of Revenue amounts to -10B INR.
What is Glenmark Life Sciences Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-23%
Over the last year, the Cost of Revenue growth was 1%. The average annual Cost of Revenue growth rates for Glenmark Life Sciences Ltd have been -3% over the past three years , -23% over the past five years .